References
- Goldhirsch A., Wood W. C., Senn H. J., Glick J. H., Gelber R. D. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J. Natl. Cancer Inst. 1995; 87: 1441–5
- Fisher B., Redmond C., Fisher E. R., Caplan R., Other contributing NSABP investigator. Relative worth of estrogen and progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients. J. Clin. Oncol. 1988; 6: 1076–87
- Truss M., Beato M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr. Rev. 1993; 14: 459–79
- Fuqua S. A. W., Wolf D. M. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Research and Treatment 1995; 35: 235–41
- Early Breast Cancer Trialists' Collaborative Study. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 71–85, 1-15
- Kiesel L. GnRH analogues in the treatment of cancer of the breast and the reproductive organs. GnRH Analogues - The State of the Art , B. Lunenfeld, V. Insler. Parthenon Publishing, CarnforthUK 1993; 123–38
- Baumann K., Kiesel L., Kaufmann M., Bastert G., Runnebaum B. Characterization of binding sites for GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Research and Treatment 1992; 25: 37–46